Sahil Khanna, MBBS, MS; Gail Hecht, MD; Erik Dubberke,MD, MSPH; Robert Orenstein, DO; Christine Lee, MD; Dale Gerding, MD
Download the presentation (5.9 MB)
Digestive Diseases Week
May 6-9, 2017, Chicago, IL
Summary
- One dose of RBX2660 administered via enema is more effective than placebo for recurrent CDI
- Responders to RBX2660
- Distinct microbiome changes from baseline in contrast to those who fail active treatment
- Responders to RBX2660
- Different microbiota composition than responders to placebo
- Placebo responders demonstrate no changes in microbiota composition after treatment
Conclusions
- RBX2660 administered via enema is an effective treatment for recurrent CDI
- Responders to active therapy have distinct microbiome profiles compared to failures
- Importance of bacterial engraftment
- Response to active therapy but not to placebo correlates with changes from baseline microbiome
- Changes in microbial profiles after microbiota-based therapies may predict treatment response